Rallybio Corporation
NASDAQ:RLYBBiotechnology
+$0.01 today
- Market cap
- $83.56M
- Beta
- -0.88
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$1.37
Volume 0.04M
Average 0.25M
Income Statement
Follow revenue through to earnings.
Revenue
$858,000.00
FY 2025 · Annual
+34.9% YoYOperating Income
-$28.06M
FY 2025 · Annual
Net Income
-$8.98M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 636K | 858K |
| Cost of Revenue | 109K | 167K | 150K | 131K | 92K |
| Gross Profit | (109K) | (167K) | (150K) | 636K | 766K |
| Gross Margin | — | — | — | 100.0% | 89.3% |
| Research & Development | 26.91M | 40.69M | 53.54M | 41.51M | 19.6M |
| Selling, General & Admin | 18.74M | 27.2M | 25.39M | 19.63M | 14.33M |
| Operating Expenses | 45.65M | 67.88M | 78.93M | 61.13M | 28.83M |
| Depreciation & Amortization | 109K | 167K | 150K | 131K | 92K |
| EBITDA | (45.39M) | (67.72M) | (78.78M) | (60.37M) | (27.97M) |
| EBITDA Margin | — | — | — | -9491.4% | -3260.1% |
| Operating Income | (45.65M) | (67.88M) | (78.93M) | (60.5M) | (28.06M) |
| Operating Margin | — | — | — | -9511.9% | -3270.9% |
| Interest Income | 54K | 1.96M | 6.15M | 4.22M | 2.19M |
| Interest Expense | 10K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1.37M) | 1.23M | 4.37M | 2.72M | 19.09M |
| Income Before Tax | (47.01M) | (67.73M) | (74.56M) | (57.78M) | (8.98M) |
| Pre-Tax Margin | — | — | — | -9084.1% | -1046.4% |
| Income Tax Expense | 0 | (1.08M) | 0 | 0 | 0 |
| Net Income | (47.01M) | (66.65M) | (74.56M) | (57.78M) | (8.98M) |
| Net Margin | — | — | — | -9084.1% | -1046.4% |
| EPS (Basic) | (11.68) | (16.72) | (14.72) | (10.64) | (1.59) |
| EPS (Diluted) | (11.68) | (16.72) | (14.72) | (10.64) | (1.59) |
| 4.02M | 3.98M | 5.06M | 5.44M | 5.63M | |
| 4.02M | 3.98M | 5.06M | 5.44M | 5.63M |
RLYB Earnings Waterfall · TTM
NASDAQ:RLYB · Revenue to Net Income
Key Ratios
Analysis
$858.0K of revenue converted into -$7.8M of net income for the selected period. Gross margin is 99.6% and net margin is -890.7%, showing how much revenue survives after costs and taxes. EPS is $-1.49, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 425 | 425 filing | Nov 12, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 425 | 425 filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 6, 2026 |
How much revenue does RLYB generate?
Rallybio Corporation (RLYB) reported $858,000.00 of revenue in fiscal 2025.
Is RLYB profitable?
Rallybio Corporation (RLYB) reported -$8.98M of net income, with a net margin of -1046.4%.
Continue the stock analysis
Jump to another research area for this company.